Very low-dose fluvastatin-valsartan combination decreases parameters of inflammation and oxidative stress in patients with type 1 diabetes mellitus

Lunder, Mojca; Janić, Miodrag; Savić, Vedran; Kanc, Karin; Šabovič, Mišo

doi:10.1016/j.diabres.2017.03.019

Cited by 9 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The causes and mechanisms of atrial fibrillation remain incompletely understood but are thought to include surgical trauma, inflammation, adrenergic activation, and oxidative stress [4][5][6][7]. Statins are believed to have anti-inflammatory and anti-oxidative properties, and in recent years a plethora of literature has emerged investigating the possible effect of statins on the development of postoperative atrial fibrillation, with initially promising but subsequently contradictory and inconclusive evidence [8][9][10][11][12][13][14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Early postoperative statin administration does not affect the rate of atrial fibrillation after cardiac surgery

Khan

Laurikka

Järvinen

et al. 2020

European Journal of Cardio-Thoracic Surgery

View full text Add to dashboard Cite

OBJECTIVES Postoperative atrial fibrillation is the most frequent complication after cardiac surgery, and the use of statins in preventing them is being extensively studied. The aim of this study was to investigate whether a pause in the administration of statins affects the occurrence of atrial fibrillation after cardiac surgery in a prospective randomized and controlled setting. METHODS A total of 301 patients without chronic atrial fibrillation with prior statin medication scheduled for elective or urgent cardiac surgery involving the coronary arteries and/or heart valves were prospectively recruited and randomized for statin re-initiation on either the first (immediate statin group) or the fifth (late statin group) postoperative day, using the original medication and dosage. The immediate statin group comprised 146 patients and the late statin group 155 patients. Except for a somewhat higher rate of males (85% vs 73%, P = 0.016) in the immediate statin group, the baseline characteristics and the distribution of procedures performed within the groups were comparable. The occurrence of postoperative atrial fibrillation and the clinical course of the patients were compared between the groups. RESULTS The incidence of atrial fibrillation was 46% and the median delay after surgery before the onset of atrial fibrillation was 3 days in both groups (P = NS). No differences were observed in the frequency of the arrhythmia in any subgroup analyses or in other major complications or clinical parameters. No adverse effects related to early statin administration were detected. CONCLUSIONS Early re-initiation of statins does not appear to affect the occurrence of postoperative atrial fibrillation. Clinical trial registration European Union Drug Regulating Authorities Clinical Trials Database (EudraCT)—2016-001655-44.

show abstract

Section: Introductionmentioning

confidence: 99%

Early postoperative statin administration does not affect the rate of atrial fibrillation after cardiac surgery

Khan

Laurikka

Järvinen

et al. 2020

European Journal of Cardio-Thoracic Surgery

View full text Add to dashboard Cite

show abstract

“…17 Similarly, the combination of a low dose of fluvastatin and valsartan was proven to act antiinflammatory and antioxidative in apparently healthy middle-aged men 18 and in patients with type II diabetes. 19 Moreover, the coadministration of captopril and valsartan reduced inflammation levels in patients after the interventional therapy for acute myocardial infarction. 20 Studies on sacubitril/valsartan revealed that sacubitril/ valsartan ameliorated atherosclerosis and inflammation in apoE−/− mice, as compared with valsartan alone.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of sacubitril/valsartan in an outpatient setting: A single-center real-world retrospective study in HFrEF patients with focus on possible predictors of clinical outcome

Fröb¹,

Sindermann²,

Reinecke³

et al. 2022

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Currently, data on sacubitril/valsartan therapy from the real-world settings are scarce and the predictors of a good clinical responsiveness to this drug are unknown.Objectives. To assess efficacy and safety profile of sacubitril/valsartan and to identify predictors for a better clinical outcome. Materials and methods.Clinical, laboratory and echocardiographic data of 95 chronic heart failure (CHF) patients with reduced ejection fraction (HFrEF) were retrospectively analyzed. A good efficacy of sacubitril/ valsartan was defined as the fulfilment of at least 2 of the following criteria: improvement of left ventricular ejection fraction (LVEF) or functional status, and reduction of N-terminal pro-brain natriuretic peptide (NT-proBNP) levels or hospitalization rates.Results. Under sacubitril/valsartan, major improvements were observed in LVEF, the New York Heart Association (NYHA) class, NT-proBNP levels, and hospitalization rates. Patients with a good efficacy of sacubitril/valsartan were characterized by initially worse LVEF (median (interquartile range (IQR)): 29.0% (23.0-33.0%) compared to 32.0% (28.5-38.0%) with more frequent nonischemic etiology (65.4% compared to 41.9%) and hospitalizations for CHF/month (0.016 (0.004-0.057) compared to 0.000 (0.000-0.012)), lower cholesterol (42.3% compared to 65. 1%), higher C-reactive protein (CRP) levels at baseline (0.5 mg/L (0.5-1.0 mg/L) compared to 0.5 mg/L (0.5-0.5 mg/L)), and a shorter timespan between CHF diagnosis and the start of sacubitril/valsartan treatment (66.0 (11.0-127.0) compared to 111 (73.0-211.0) months) (p < 0.05 each). In a multivariate Cox analysis, only the last 2 parameters were shown to be independent predictors of good clinical responsiveness to sacubitril/valsartan (hazard ratio (HR) = 1.263, 95% confidence interval (95% CI) = [1.048; 1.521]; HR = 0.992, 95% CI = [0.987; 0.997], p < 0.05, respectively).Conclusions. Sacubitril/valsartan improved LVEF, NYHA class, NT-proBNP levels, and hospitalization rates, mostly without relevant side effects. The independent predictors of a good clinical efficacy were higher CRP levels at baseline and a shorter delay between CHF diagnosis and the initialization of sacubitril/valsartan therapy.

show abstract

“…The risks of composite cardiovascular event, myocardial infarction, heart failure, ischemic stroke, cardiovascular death, and all-cause death were significantly lower in the rosuvastatin group than the placebo group. Statins have been shown to exert protective effects against cardio-and cerebro-vascular diseases (25, [36][37][38]. The results of the HOPE-3 (Heart Outcomes Prevention Evaluation) trial have revealed that low-dose rosuvastatin decreases cardiovascular diseases in participants with two or more healthful lifestyle factors (HR: 0.74 with 95% CI: 0.62-0.90) and in participants with fewer than two factors (HR: 0.79 with 95% CI: 0.61-1.01) (25).…”

Section: Discussionmentioning

confidence: 99%

Attenuating the Variability of Lipids Is Beneficial for the Hypertension Management to Reduce the Cardiovascular Morbidity and Mortality in Older Adults

Dong

Liu

Zhao

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Objective: To investigate the beneficial of attenuating the variability of lipids to the hypertension management in older adults.Methods: Between April 2008 and November 2010, 1,244 hypertensive patients aged ≥60 years were recruited and randomized into placebo and rosuvastatin groups. Outcomes and inter-visit plasma lipids variability were assessed.Results: Over an average follow-up of 83.5 months, the coefficients of variation (CVs) in total cholesterol (TCHO), triglycerides, high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c) were significantly lower in the rosuvastatin group than the placebo group (p < 0.05). The risks of composite cardiovascular event, myocardial infarction, coronary revascularization, heart failure, total stroke, ischemic stroke, cardiovascular death, and all-cause death were significantly lower in the rosuvastatin group than the placebo group (all p < 0.05). The differences in the risks were significantly diminished after the CVs for TCHO, triglycerides, HDL-c, and LDL-c were separately included as confounders. One-SD of CVs for TCHO, triglycerides, HDL-c, and LDL-c increment were significantly associated with the risks of composite cardiovascular event, myocardial infarction, heart failure, total stroke, ischemic stroke, cardiovascular death, and all-cause death, respectively (all p < 0.05).Conclusions: Rosuvastatin significantly attenuated the intra-visit variability in lipids and decreased the risk of cardiovascular mortality and morbidity. Controlling the variability of lipids is as important as antihypertensive treatment to reduce the cardiovascular morbidity and mortality in the management of older hypertensive patients.Clinical Trial Registration:ChiCTR.org.cn, ChiCTR-IOR-17013557.

show abstract

Very low-dose fluvastatin-valsartan combination decreases parameters of inflammation and oxidative stress in patients with type 1 diabetes mellitus

Cited by 9 publications

References 22 publications

Early postoperative statin administration does not affect the rate of atrial fibrillation after cardiac surgery

Early postoperative statin administration does not affect the rate of atrial fibrillation after cardiac surgery

Efficacy and safety of sacubitril/valsartan in an outpatient setting: A single-center real-world retrospective study in HFrEF patients with focus on possible predictors of clinical outcome

Attenuating the Variability of Lipids Is Beneficial for the Hypertension Management to Reduce the Cardiovascular Morbidity and Mortality in Older Adults

Contact Info

Product

Resources

About